BPC-157 has no approved human dose — it is not FDA-approved for any use, and no controlled human trial has established a dosing regimen. Every number in this bpc 157 dosage guide comes from published preclinical (animal) research, cited study by study. Below: the bpc 157 dosage tiers used across the literature, how bpc 157 dose protocols differ by administration route, and what the evidence actually says about oral use. If you are looking for what the science tested — rather than what forums claim — this is that guide.
The Short Answer
- No human dose exists. All published dosing data comes from rodent studies, mostly from one research group (Sikirić et al., University of Zagreb).
- The classic research doses are 10 µg/kg, 10 ng/kg, and 10 pg/kg given daily by intraperitoneal injection in rats — a range spanning six orders of magnitude, deliberately chosen to map a wide therapeutic window.
- Oral BPC-157 worked in animals. In a head-to-head rat study (Cerovecki et al. 2010), oral dosing matched injected dosing for ligament healing at 90 days — consistent with BPC-157’s unusual stability in gastric juice (>24 hours).
- The “200–500 mcg/day” figures you see online are informal extrapolations, not derived from any published human study. The math behind them does not hold up (more below).
Now the full breakdown, study by study.
What Is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide (sequence GEPPPGKPADDAGLV, ~1419.5 Da) derived from a protective protein found in human gastric juice. It was systematically characterized in the 1990s by Predrag Sikirić’s group, and most of the 100+ peer-reviewed papers on it come from that lab — almost all in rodent models.
Its standout property: BPC-157 remains stable in human gastric juice for over 24 hours, which is extraordinary for a peptide and the reason oral administration became a serious research question rather than a non-starter. Research interest has been steady since the 1990s, with the literature now exceeding 100 peer-reviewed papers — though readers should know that the great majority come from a single research group, which is both the field’s strength (consistency) and its limitation (independent replication is thin).
BPC-157 Dosage Chart: Quick Reference
For quick scanning, here are the bpc 157 dosing protocols from the published literature condensed into one view. Remember: every entry below is an animal study protocol, not a recommendation.
| Goal of this chart | What the literature used |
|---|---|
| Standard daily dose | 10 µg/kg, i.p., once daily (most common across tendon/ligament studies) |
| Low-end tested dose | 10 pg/kg, i.p., once daily — six orders of magnitude below the standard |
| Oral protocol | 10 µg/kg/day in drinking water (bpc 157 oral administration in rats) |
| Single-dose protocol | 200 or 2 µg/kg i.p. once (spinal cord injury model) |
| Topical protocol | 1 µg/g cream, once daily (wound models) |
| Typical study length | 14–30 days; longest published exposure: one year |
Use this chart to orient yourself in the literature — not to plan anything else.
BPC-157 Dosage in Published Research
The dosing literature is unusually consistent, because most of it comes from one lab using a standardized protocol. Here are the tiers, with representative studies:
| Dose (rats) | Route | Frequency | Example study |
|---|---|---|---|
| 10 µg/kg | Intraperitoneal (i.p.) | Daily | Starešinić et al. 2003 — transected Achilles tendon; Krivić et al. 2008 — early tendon healing |
| 10 ng/kg | Intraperitoneal (i.p.) | Daily | Sikirić et al. 2000 — antidepressant models (also tested 10 µg/kg) |
| 10 pg/kg | Intraperitoneal (i.p.) | Daily | Same program — establishing effects across six orders of magnitude |
| 20 µg/kg | Intraperitoneal (i.p.) | Daily | “Standard experimental dose” in ischemia-reperfusion and other models, per multiple papers |
| 10 µg/kg/day | Oral (drinking water) | Daily | Cerovecki et al. 2010 — MCL transection, 90-day ligament healing |
| 200 or 2 µg/kg | Single i.p. dose | Once | Spinal cord injury model — given 10 min post-injury, 360-day follow-up |
All doses above are per the cited animal studies — not recommendations. BPC-157 has no established human dose.
Oral vs Injectable: What the Studies Show
This is the most practically interesting question in the BPC-157 literature, and the honest answer is: the data is genuinely mixed.
- Oral works in animals — head-to-head. Cerovecki et al. 2010 (Journal of Orthopaedic Research) compared oral BPC-157 (in drinking water) against intraperitoneal injection in rats with transected medial collateral ligaments. At 90 days, ligament healing was comparable between routes — the strongest direct evidence that oral administration is not wasted in this model.
- Injected pharmacokinetics are now mapped. He et al. 2022 (Frontiers in Pharmacology) — the only regulatory-grade PK study — found intramuscular bioavailability of 14–19% in rats and 45–51% in dogs, with plasma half-life under 30 minutes and peak at ~3 minutes. No accumulation over 7 days of repeat dosing.
- Oral bioavailability: conflicting numbers. Published figures disagree sharply — from below detection limits (<1%) in one dataset to 44–62% in a 2014 rat study, with modeling estimates in between. There is no published absolute oral bioavailability percentage to quote with confidence. Any website stating a precise oral BA% for BPC-157 is not citing a paper.
- Salt form matters. Rat studies found the arginine salt form had notably higher oral bioavailability than the acetate form — a detail most vendor pages omit.
- No subcutaneous PK data exists. Despite subcutaneous being the most discussed route online, there is no published pharmacokinetic study of subcutaneous BPC-157, and no head-to-head s.c. vs i.m. comparison.
How Often and How Long? Study Protocols
- Frequency: once daily in the overwhelming majority of published protocols. The sub-30-minute plasma half-life has prompted discussion about whether more frequent dosing would matter, but no study has established an optimal frequency.
- Duration: single dose to one year. Protocols range from a single post-injury injection, through 7–30 day courses, up to a one-year study (adjuvant arthritis model) — the longest published exposure.
- Escalation: none. Unlike GLP-1 drugs, BPC-157 studies do not use dose-titration schedules; animals receive a fixed daily dose throughout.
What About the “200–500 mcg/Day” Figures Online?
Almost every peptide forum quotes 200–500 mcg per day as “the” BPC-157 dose. Here is what those numbers actually are: informal extrapolations from rodent doses, not derived from any human study (traced via PMC13210877).
The arithmetic does not survive scrutiny. Take the classic 10 µg/kg rat dose:
- Naive scaling: 10 µg/kg × 70 kg = 700 µg — already above the forum range.
- Proper allometric scaling (body-surface-area method, the FDA’s standard for first-in-human estimates): ≈ 113 µg — well below the forum range.
- Forum range (200–500 µg): sits between the two, matching neither method. It has no methodological basis.
This does not mean the numbers are “wrong” in any verifiable sense — there is no human data to compare against. It means they are not science. Anyone presenting them as research-derived is misrepresenting the literature.
BPC-157 and TB-500 Together: What the One Study Found
The “Wolverine Stack” — BPC-157 plus TB-500 — is peptide-community lore built on the idea that the two compounds’ mechanisms complement each other. Until 2026, no published study had ever tested the combination. Then came the first one:
- Biçer et al. 2026 (Joint Diseases and Related Surgery): 32 male rats, transected Achilles tendon with surgical repair, four groups (control / BPC-157 / TB-500 / combination), daily intraperitoneal injections for 30 days (BPC-157 10 mcg/kg/day + TB-500 60 mcg/kg/day).
- Result: the combination was not better than either compound alone on any endpoint. Only the TB-500-only group reached statistical significance for maximum tendon rupture load. The authors describe it as exploratory.
- Bottom line: “1+1>2 synergy” is community lore contradicted by the only controlled study to date. Mechanistic complementarity remains theoretical; no human combination study exists.
Also read: our BPC-157 product page lists available purities with HPLC/MS documentation and third-party COA verification on every batch.
Safety: What Preclinical Studies Report
- No acute lethality observed across the full tested range (6 µg/kg to 20 mg/kg, multiple routes) — which is precisely why no LD50 has been established. Absence of an LD50 is not a safety claim; it reflects that lethal doses were never reached in testing.
- Repeat-dose studies (up to 6 weeks) reported no abnormalities in liver, spleen, thymus, or stomach wall.
- Teratogenicity testing (0.2–4 mg/kg during gestation days 6–15) showed no teratogenic effects in the tested model.
- The critical limitation: none of this substitutes for human safety data, which does not exist in controlled-trial form. Preclinical safety cannot be extrapolated to humans.
Frequently Asked Questions
Does oral BPC-157 work?
In rats, yes — at least for the studied endpoints. Cerovecki et al. 2010 found oral BPC-157 matched injected BPC-157 for ligament healing over 90 days, consistent with the peptide’s >24-hour stability in gastric juice. Published oral bioavailability percentages conflict and should be treated skeptically.
Can you take BPC-157 orally?
Published animal studies used oral BPC-157 in drinking water at 10 µg/kg/day with measurable effects. Whether oral administration is “effective” in humans is unstudied — there are no controlled human trials of any route.
How long do BPC-157 studies run?
Published protocols range from a single dose to 30-day courses, with the longest study running one year. Most tendon and tissue studies use 14–30 days of daily dosing in rats.
How often is BPC-157 dosed in studies?
Once daily in nearly all published protocols. No study has compared dosing frequencies, so there is no evidence-based “optimal” schedule.
How long can you take BPC-157 in research settings?
Published animal exposures run from a single dose to a full year, with 14–30 days being typical. There is no published “maximum safe duration” — the one-year adjuvant arthritis study is simply the longest anyone has run.
What is a standard bpc 157 dose in the literature?
If “standard” means “most used,” it is 10 µg/kg given intraperitoneally once daily in rats — the workhorse protocol of the Sikirić lab across tendon, ligament, and tissue studies. A bpc 157 dose of 20 µg/kg appears as the labeled “standard experimental dose” in several ischemia-reperfusion papers. Neither is a human dose.
How quickly does BPC-157 work in studies?
It depends on the model. Anti-inflammatory markers shifted within days in early tendon-healing studies (Krivić et al. 2008, days 1–4); functional and biomechanical endpoints were typically measured at 2–12 weeks. There is no human timeline.
Is the BPC-157 + TB-500 combination proven?
No. The only published controlled combination study (Biçer et al. 2026) found no advantage of the combination over either peptide alone. Synergy claims are community lore, not science.
Need research-grade BPC-157 with verified purity? This bpc 157 dosage guide is only useful if the material matches its label. Browse our BPC-157 collection — every batch ships with HPLC and mass spectrometry documentation, plus third-party COA verification.
Advanced research: BPC-157 and TB-500 — the full evidence review of the “Wolverine Stack,” from the mechanisms each peptide is studied for to what the first (and only) combination trial actually found.
Disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. BPC-157 is not approved by any regulatory authority for human use; all doses cited are from published animal studies and are not recommendations. Peptides sold on this site are for laboratory research use only and are not intended for human or veterinary use. Consult a qualified healthcare professional for medical decisions.
Leave a Reply